A 52-year-old man with Stage 4 CKD (eGFR 18 mL/min/1.73m²) due to diabetic nephropathy presents with fatigue and dyspnea on exertion for 3 months. His wife reports he has become increasingly irritable and forgetful. Laboratory investigations reveal: Hemoglobin 7.2 g/dL, MCV 88 fL, reticulocyte count 0.8%, serum creatinine 3.8 mg/dL, eGFR 18 mL/min/1.73m², serum iron 65 μg/dL (normal), ferritin 180 ng/mL (normal), TIBC 240 μg/dL (normal). Peripheral blood smear shows normocytic normochromic RBCs. Serum PTH is markedly elevated at 380 pg/mL. What is the primary mechanism responsible for the anemia in this patient?

Explanation

## Pathophysiology of CKD-Associated Anemia **Key Point:** Anemia of chronic kidney disease (CKD-related anemia) is primarily caused by **decreased erythropoietin (EPO) production** by the failing kidneys, not iron or vitamin deficiency. ### Why EPO Deficiency Occurs The kidneys produce ~90% of circulating EPO. As GFR declines below 45 mL/min/1.73m², the peritubular fibroblasts (EPO-producing cells) are progressively lost due to: - Glomerular and tubular damage - Chronic hypoxia from uremia - Accumulation of uremic toxins that suppress EPO synthesis ### Laboratory Clues in This Case | Finding | Interpretation | |---------|----------------| | Hemoglobin 7.2 g/dL | Moderate anemia | | MCV 88 fL | Normocytic (rules out iron/B12 deficiency) | | Reticulocyte count 0.8% | **Inappropriately LOW** for the degree of anemia (should be >2% if bone marrow responding) | | Normal iron studies | Rules out iron deficiency | | eGFR 18 mL/min/1.73m² | Stage 4 CKD — EPO production severely impaired | **Clinical Pearl:** The **inappropriately low reticulocyte count** in the setting of normocytic anemia and advanced CKD is the hallmark of EPO deficiency. A healthy bone marrow would mount a reticulocytosis >2–3% in response to Hb 7.2 g/dL. ### Secondary Factors (Not Primary) While secondary hyperparathyroidism (PTH 380 pg/mL) can contribute to: - Shortened RBC lifespan (mild hemolysis) - Bone marrow fibrosis (reducing erythropoiesis) - Uremic toxin accumulation ...these are **secondary mechanisms**, not the primary driver. **High-Yield:** CKD anemia is **EPO-responsive** — ESA (erythropoiesis-stimulating agent) therapy is the first-line treatment, not iron or transfusion alone. ### Management Approach 1. Confirm EPO deficiency (serum EPO level typically <10 mIU/mL in CKD Stage 4) 2. Initiate ESA (e.g., darbepoetin alfa, epoetin alfa) 3. Optimize iron status (target ferritin 100–500 ng/mL, TSAT 20–50%) 4. Address secondary hyperparathyroidism (phosphate binders, vitamin D analogs, calcimimetics) 5. Manage blood pressure and slow CKD progression [cite:Harrison 21e Ch 279]